ICP-248 Clinical Trials

5 actively recruiting trials across 2 locations

Pipeline

Phase 1: 3Phase 2: 1Phase 2/3: 1

Top Sponsors

Beijing InnoCare Pharma Tech Co., Ltd.4
InnoCare Pharma Inc.1

Indications

Cancer5
Relapsed or Refractory Mantle Cell Lymphoma (MCL)1
Mature B-cell Malignancies1
Hematological Malignancies1
Myelodysplastic Syndromes (MDS)1

Other3 trials

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

Phase 2

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

Phase 2/3

The Study of ICP-248 in Patients With Mature B-cell Malignancies

Phase 1

Plantation, Florida1 trial

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

BRCR Medical Center

Phase 1

New York, New York1 trial

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

NYU Langone Health

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.